SOA Research Report: Reimagining Pharmacy Financing
Recently AHP consulting actuaries Joan Barrett, Tony Pistilli, Nathan Stokes, and Gregory Warren, teamed up to look into [...]
Biosimilars: Maximizing Adoption
To achieve savings benefits from the coming wave of biosimilars, biosimilars must be adopted by prescribers, members, and payers (through their formulary strategies). While previous...
Biosimilars: Payer Decision Making
Once the first Humira biosimilar, Amjevita, launched in the United States in January, payers needed to begin making decisions about coverage not only for Amjevita but for all the other Humira...
The Financial Impact of Biosimilars
There is a coming wave of changes arriving soon to the pharmacy market in the form of biosimilars. And that coming wave has a big event in 2023: the launch of Humira biosimilars, which...
The Big Event: Humira Biosimilar Launches
Today is the day! The Big Event of 2023 is the launch of multiple Humira biosimilars which begins today with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita is the first step in the Big Event...
Biosimilars: The Coming Wave
There is a big wave of changes coming to the pharmacy market. The extent of the impact this wave will bring is not yet fully known, but there are trends we can follow that help predict what this change will look like...
Biosimilars: A Brief Introduction
The coming market introduction of several significant biosimilars is predicted to bring a wave of change to the pharmacy benefits status quo. As healthcare consultants, we have been watching the swell develop and have put together this primer to help educate...
Pharmacy Provisions of the Inflation Reduction Act
I read the 725-page draft of the Deficit Reduction Act[1] so you don’t have to. Well, I skimmed 427 pages of it while focusing on the 164 pages which make significant changes to prescription drugs. This article outlines...